Headache News and Research

Latest Headache News and Research

Complementary medicine risks: an interview with Dr Andrew Boyden, NPS MedicineWise

Complementary medicines include products containing herbs, vitamins, minerals, nutritional supplements, homoeopathic medicines, certain aromatherapy products and traditional Chinese medicines. For this reason they are also called herbal, natural or alternative medicines.

26 Feb 2013

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.

25 Feb 2013

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.

23 Feb 2013

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

CSL Behring today announced that the United States Food and Drug Administration has approved a 40 g (400 mL) vial size for Privigen, immune globulin intravenous [human].

21 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

FDA approves Novartis’ Zortress to prevent organ rejection after liver transplantation in adults

Novartis announced today that the US Food and Drug Administration (FDA) has approved Zortress (everolimus) for the prophylaxis of organ rejection in adult patients receiving a liver transplant.

16 Feb 2013

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Genzyme, a Sanofi company, today announced positive new data from the Phase 3 ENGAGE and ENCORE studies of eliglustat tartrate, its investigational oral therapy for Gaucher disease type 1.

15 Feb 2013

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today the U.S. commercial launch of UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

14 Feb 2013

Nerve stimulation could stave off migraine attacks

Transcutaneous stimulation of the trigeminal nerve has shown promise as a treatment for migraine, according to results of a randomized controlled trial.

14 Feb 2013

LASAG trial for severe influenza initiated

...

12 Feb 2013

Tips on avoiding a Valentine's Day Headache

February 14 is right around the corner, and no one wants to spend Valentine's day, or the day after, with a severe headache and some of its accompaniments – nausea, vomiting, sensitivity to light and sound. And you certainly don't want your gift to be the culprit in producing a headache.

12 Feb 2013

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Biogen Idec and Swedish Orphan Biovitrum (Sobi) released data that confirmed the ability of investigational recombinant factors VIII Fc fusion protein (rFVIIIFc) and IX Fc fusion protein (rFIXFc) to provide long-lasting protection from bleeding with fewer injections than are required with the current standard of care for people with hemophilia.

10 Feb 2013

Migraine, epilepsy and genetics: an interview with Dr. Melodie Winawer

This work is the product of an extraordinary consortium called the Epilepsy Phenome/Genome project (EPGP). It is a consortium of 27 centres in the U.S. and internationally with several hundred physicians and staff who have worked together to enrol more than 4000 patients with epilepsy and their family members.

7 Feb 2013

Study: 10 to 15% of people with TIAs will experience strokes within three months

Each year, as many as 500,000 Americans experience mini strokes called transient ischemic attacks (TIAs). Symptoms quickly go away, usually within an hour, and many people don't seek treatment. But 10 to 15 percent of people who experience TIAs will experience full-blown strokes within three months, and 40 percent of these strokes will occur in the first 24 hours, according to an article by three Loyola University Medical Center neurologists in the journal Expert Review of Neurotherapeutics.

6 Feb 2013

ATI Neurostimulation System demonstrates clinical effectiveness in treating cluster headache

Autonomic Technologies, Inc. (ATI), the developer of the ATI Neurostimulation System designed for the treatment of severe headaches, today announced results of their clinical study in cluster headache, now published online in Cephalalgia.

5 Feb 2013

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

Gilead Sciences today announced topline results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide sofosbuvir in combination with ribavirin (FISSION) and in combination with ribavirin and pegylated interferon (NEUTRINO) among treatment-naïve patients with chronic hepatitis C virus (HCV) infection.

5 Feb 2013

Hyperion Therapeutics receives FDA approval for Ravicti to treat urea cycle disorders

The U.S. Food and Drug Administration today approved Ravicti (glycerol phenylbutyrate) for the chronic management of some urea cycle disorders (UCDs) in patients ages 2 years and older.

1 Feb 2013

Study supports hypothesis that disulfiram reduces drug consumption by blocking DβH

Disulfiram was the first medication approved for the treatment of alcoholism over 50 years ago. It works, at least in part, by preventing the metabolism of an alcohol by-product, acetaldehyde. High levels of acetaldehyde in the body quickly cause unpleasant symptoms, including nausea, vomiting, headache, and accelerated heart rate. Thus, disulfiram provides a very strong incentive to avoid drinking.

1 Feb 2013

Delaware District Court rules in favor of Pfizer in RAPAMUNE patent case

Pfizer Inc. said today that the United States District Court for the District of Delaware ruled that Pfizer's patent covering a method for using sirolimus, the active ingredient in RAPAMUNE®, for the inhibition of organ transplant rejection is valid and infringed.

31 Jan 2013

Pediatric migraine drugs show limited or no efficacy

There is limited evidence supporting the efficacy of trazodone and topiramate in the prevention of pediatric episodic migraine headaches, show results from a meta-analysis.

30 Jan 2013

Headache News and Research

Latest Headache News and Research

Complementary medicine risks: an interview with Dr Andrew Boyden, NPS MedicineWise

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

FDA approves Novartis’ Zortress to prevent organ rejection after liver transplantation in adults

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Nerve stimulation could stave off migraine attacks

LASAG trial for severe influenza initiated

Tips on avoiding a Valentine's Day Headache

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Migraine, epilepsy and genetics: an interview with Dr. Melodie Winawer

Study: 10 to 15% of people with TIAs will experience strokes within three months

ATI Neurostimulation System demonstrates clinical effectiveness in treating cluster headache

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

Hyperion Therapeutics receives FDA approval for Ravicti to treat urea cycle disorders

Study supports hypothesis that disulfiram reduces drug consumption by blocking DβH

Delaware District Court rules in favor of Pfizer in RAPAMUNE patent case

Pediatric migraine drugs show limited or no efficacy

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Headache News and Research

Latest Headache News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in